Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 6 (2009), Issue 2 (February)

1. NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.
   Cancer Immunol Immunother, 58(4): 575-87. [Abstract] [Full-text]
2. A fast and efficient HLA multimer-based sorting procedure that induces little apoptosis to isolate clinical grade human tumor specific T lymphocytes.
   Cancer Immunol Immunother, 58(4): 553-66. [Abstract] [Full-text]
3. Immune stimulatory antigen loaded particles combined with depletion of regulatory T-cells induce potent tumor specific immunity in a mouse model of melanoma.
   Cancer Immunol Immunother, 58(4): 517-30. [Abstract] [Full-text]
4. In vivo anti-melanoma efficacy of allo-restricted CTLs specific for melanoma expanded by artificial antigen-presenting cells.
   Cancer Immunol Immunother, 58(4): 629-38. [Abstract] [Full-text]
5. DC therapy induces long-term NK reactivity to tumors via host DC.
   Eur J Immunol, 39(2): 457-68. [Abstract] [Full-text]
6. Positive interaction between light iris color and ultraviolet radiation in relation to the risk of uveal melanoma: a case-control study.
   Ophthalmology, 116(2): 340-8. [Abstract] [Full-text]
7. Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation.
   Mol Cell, 33(2): 237-47. [Abstract] [Full-text]
8. Molecular regulation of vasculogenic mimicry in human uveal melanoma cells: role of helix-loop-helix Id2 (inhibitor of DNA binding 2).
   Graefes Arch Clin Exp Ophthalmol, 247(3): 411-9. [Abstract] [Full-text]
9. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
   Int J Cancer, 124(7): 1594-604. [Abstract] [Full-text]
10. Large speckled lentiginous naevus superimposed with Spitz naevi: sequential digital dermoscopy may lead to unnecessary excisions triggered by dynamic changes.
    Clin Exp Dermatol, 34(2): 212-5. [Abstract] [Full-text]
11. Speckled lentiginous naevus: which of the two disorders do you mean?
    Clin Exp Dermatol, 34(2): 133-5. [Abstract] [Full-text]
12. Metastatic malignant melanoma associated with vitiligo-like depigmentation.
    Clin Exp Dermatol, 34(2): 209-11. [Abstract] [Full-text]
13. Cancer risk after exposure to treatments for ovulation induction.
    Am J Epidemiol, 169(3): 365-75. [Abstract] [Full-text]
14. Recall bias in melanoma risk factors and measurement error effects: a nested case-control study within the Norwegian Women and Cancer Study.
    Am J Epidemiol, 169(3): 257-66. [Abstract] [Full-text]
15. Invited commentary: Recall bias in melanoma -- much ado about almost nothing?
    Am J Epidemiol, 169(3): 267-70; discussion 271-2. [Abstract] [Full-text]
16. Integrating BRAF/MEK inhibitors into combination therapy for melanoma.
    Br J Cancer, 100(3): 431-5. [Abstract] [Full-text]
17. Molecular and phenotypic analysis of poorly differentiated sinonasal neoplasms: an integrated approach for early diagnosis and classification.
    Hum Pathol, 40(3): 283-92. [Abstract] [Full-text]
18. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).
    J Immunol, 182(4): 2030-40. [Abstract] [Full-text]
19. A phase 2, randomized study of SB-485232, rhIL-18, in patients with previously untreated metastatic melanoma.
    Cancer, 115(4): 859-68. [Abstract] [Full-text]
20. Meta-analysis of sentinel lymph node positivity in thin melanoma (<or=1 mm).
    Cancer, 115(4): 869-79. [Abstract] [Full-text]
21. Cytotoxic, genotoxic and oxidative stress induced by 1,4-naphthoquinone in B16F1 melanoma tumor cells.
    Toxicol In Vitro, 23(2): 242-50. [Abstract] [Full-text]
22. Inadvertent evisceration of eyes containing uveal melanoma.
    Arch Ophthalmol, 127(2): 141-5. [Abstract] [Full-text]
23. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor.
    Proc Natl Acad Sci U S A, 106(6): 1814-9. [Abstract] [Full-text]
24. Surgery for melanoma metastases of the gastrointestinal tract: indications and results.
    Eur J Surg Oncol, 35(3): 313-9. [Abstract] [Full-text]
25. Gene expression analysis of terminal differentiation of human melanoma cells highlights global reductions in cell cycle-associated genes.
    Gene, 433(1): 32-9. [Abstract] [Full-text]
26. High-resolution magic angle spinning nuclear magnetic resonance analysis of metabolic changes in melanoma cells after induction of melanogenesis.
    Anal Biochem, 386(2): 282-4. [Abstract] [Full-text]
27. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth.
    Cancer Res, 69(4): 1324-33. [Abstract] [Full-text]
28. Integral role of transcription factor 8 in the negative regulation of tumor angiogenesis.
    Cancer Res, 69(4): 1678-84. [Abstract] [Full-text]
29. Autotaxin protects MCF-7 breast cancer and MDA-MB-435 melanoma cells against Taxol-induced apoptosis.
    Oncogene, 28(7): 1028-39. [Abstract] [Full-text]
30. Alternatively spliced Spalax heparanase inhibits extracellular matrix degradation, tumor growth, and metastasis.
    Proc Natl Acad Sci U S A, 106(7): 2253-8. [Abstract] [Full-text]
31. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/-granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advanced metastatic melanoma: Eastern Cooperative Oncology Group Phase II Trial E1696.
    Clin Cancer Res, 15(4): 1443-51. [Abstract] [Full-text]
32. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
    Clin Cancer Res, 15(4): 1384-92. [Abstract] [Full-text]
33. Combining the endoplasmic reticulum stress-inducing agents bortezomib and fenretinide as a novel therapeutic strategy for metastatic melanoma.
    Clin Cancer Res, 15(4): 1192-8. [Abstract] [Full-text]
34. The activation of human endogenous retrovirus K (HERV-K) is implicated in melanoma cell malignant transformation.
    Exp Cell Res, 315(5): 849-62. [Abstract] [Full-text]
35. Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis.
    Am J Pathol, 174(3): 1009-16. [Abstract] [Full-text]
36. Ipilimumab: controversies in its development, utility and autoimmune adverse events.
    Cancer Immunol Immunother, 58(5): 823-30. [Abstract] [Full-text]
37. TCR transgenes and transgene cassettes for TCR gene therapy: status in 2008.
    Cancer Immunol Immunother, 58(5): 809-22. [Abstract] [Full-text]
38. Characterization of MHC class-I restricted TCRalphabeta+ CD4- CD8- double negative T cells recognizing the gp100 antigen from a melanoma patient after gp100 vaccination.
    Cancer Immunol Immunother, 58(5): 709-18. [Abstract] [Full-text]
39. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Cancer Immunol Immunother, 58(5): 719-28. [Abstract] [Full-text]
40. The immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines.
    Cancer Immunol Immunother, 58(5): 665-75. [Abstract] [Full-text]
41. Immunosensitization with a Bcl-2 small molecule inhibitor.
    Cancer Immunol Immunother, 58(5): 699-708. [Abstract] [Full-text]
42. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth.
    Cancer Immunol Immunother, 58(5): 769-75. [Abstract] [Full-text]
43. Primary malignant melanoma of the cervix: report of a case.
    Arch Gynecol Obstet, 279(4): 573-5. [Abstract] [Full-text]
44. Activation of the FGF2/FGFR1 autocrine loop for cell proliferation and survival in uveal melanoma cells.
    Invest Ophthalmol Vis Sci, 50(3): 1047-57. [Abstract] [Full-text]
45. 6-Benzylaminopurine stimulates melanogenesis via cAMP-independent activation of protein kinase A.
    Arch Dermatol Res, 301(3): 253-8. [Abstract] [Full-text]
46. Proposed quality standards for regional lymph node dissections in patients with melanoma.
    Ann Surg, 249(3): 473-80. [Abstract] [Full-text]
47. Increased UVA exposures and decreased cutaneous Vitamin D(3) levels may be responsible for the increasing incidence of melanoma.
    Med Hypotheses, 72(4): 434-43. [Abstract] [Full-text]

© 2004-2010 Melanoma Research Today. All Rights Reserved.